Imaging Endpoints

Conducting the largest and most complex trials in the industry

[Imaging Endpoints @ImagingEndpoint]

Join us at Booth #19023 to meet our medical, scientific, and operational experts and discuss how Imaging Endpoints can help optimize your clinical development programs.

https://t.co/YrDd7wLDHH

📅 ASCO Annual Meeting 2026
📍 Chicago, IL
🗓️ May 30 – June 1
📌 Booth #19023

[Imaging Endpoints @ImagingEndpoint]

Imaging Endpoints’ Founder and Chief Medical Officer, Ron Korn, will be participating in the RAISE* Community Meeting panel:
“Radiopharmaceutical Therapy in Oncology: Practical Integration for Practicing Oncologists.”

[Imaging Endpoints @ImagingEndpoint]

We’re ready for SNMMI 2026!

Meet the Imaging Endpoints team at Booth #522.

📅 May 30 – June 2
📍 Los Angeles Convention Center, Los Angeles, CA

👉 Schedule your meeting now: https://t.co/fUcgTuRvBB or "Scan the QR code"

[Imaging Endpoints @ImagingEndpoint]

Advances in imaging, especially radiomics and the emergence of AI and machine learning for downstream analysis, are transforming lung cancer detection and management in clinical trials.

Full Article: https://t.co/DmcK7CSIYd

[Imaging Endpoints @ImagingEndpoint]

We’re ready for ASCO 2026!

Meet the Imaging Endpoints team at Booth #19023 to explore how we’re advancing oncology trials with customized imaging strategies, regulatory expertise, and cutting-edge technologies.
👉 Schedule your meeting now: https https://t.co/46j0ObQ7jq

[Imaging Endpoints @ImagingEndpoint]

Integrating PSMA PET and Molecular Imaging into Response Assessment for Prostate Cancer Clinical Trials

Read the full story here.
https://t.co/UiYZ9by1eQ

[Imaging Endpoints @ImagingEndpoint]

The Expanding Role of Imaging in Theranostic Trials for Hematologic Malignancies

Read the full post here: https://t.co/EwIIZNIZaz

#Theranostics #ClinicalTrials #MolecularImaging #RadioligandTherapy #HematologicMalignancies #NuclearMedicine #PrecisionMedicine #ImagingEndpoints

[Imaging Endpoints @ImagingEndpoint]

Dr. Ron Korn, MD, PhD will be attending ASCO GU 2026 in San Francisco.

We welcome the opportunity to connect.

Schedule time with Dr. Korn here: https://t.co/sgN4eclvZi

#ASCOGU #GUOncology #ClinicalTrials #Radiopharma #OncologyResearch

[Imaging Endpoints @ImagingEndpoint]

SCOPE brings together clinical operations leaders focused on improving trial execution and outcomes. If you are interested in discussing how IE optimized imaging approaches can help reduce operational risk and support trial success, let’s connect.
https://t.co/kdRb4DIIxn

[Imaging Endpoints @ImagingEndpoint]

Modern NET trials rely on quantitative SSTR PET, dosimetry, and harmonized central imaging. Integrating RECIST 1.1 with SSTR PET and lesion-level dosimetry supports better patient selection, precision PRRT, and submission-ready trial data.

Read More: https://t.co/dA3c13dSUC

[Imaging Endpoints @ImagingEndpoint]

Excited to announce that Imaging Endpoints will be at the ASCO GI Cancers Symposium 2026 in San Francisco! 🌟

🗓️ When: January 08-09, 2026
📍 Where: Table #12

👉 Schedule a meeting with us today! https://t.co/diqpQ9mCU0

Together, let’s change the image of what’s possible.

[Imaging Endpoints @ImagingEndpoint]

HCC’s rising mortality makes precise imaging essential in trials. Integrating targeted PET tracers with LI-RADS and RECIST/mRECIST improves staging, treatment allocation, and early response assessment.

Read more: https://t.co/IFJxOt7Ec5

#HCC #OncologyTrials #MedicalImaging

[Imaging Endpoints @ImagingEndpoint]

We’re thrilled to participate in this year’s ASH Annual Meeting from December 6th–8th at Booth #981!

Let’s connect and discuss how we can collaborate to revolutionize clinical trials with state-of-the-art solutions.

Click here to secure your spot: https://t.co/gtn21pgzBE

[Imaging Endpoints @ImagingEndpoint]

CD8 PET Imaging: Advancing Immunotherapy and Trial Decisions

Imaging Endpoints is leading CD8 PET integration in trials, mapping immune deserts, informing therapy adjustments, and identifying patients most likely to benefit.

Read full article here at: https://t.co/s2ZsvUjq9i

[Imaging Endpoints @ImagingEndpoint]

We’re excited to connect with you at SITC 2025 in Maryland, USA (Nov 7–8)!

📍 Booth #339
📅 Schedule a meeting with Dr. Korn: https://t.co/KnHQsYPxb0

Let’s explore how we can enhance your clinical trials together.

[Imaging Endpoints @ImagingEndpoint]

Have you ever wondered if there’s a more dynamic way to assess solid tumor treatment efficacy or predict when a tumor will double or shrink by half?
👉Discover how eTGK models transform tumor response evaluation https://t.co/QKnhFAM7Vo
#ClinicalTrials #Oncology #ImagingEndpoints

[Imaging Endpoints @ImagingEndpoint]

Imaging Endpoints congratulates Anthony G. Letai, MD, PhD, on becoming the 18th Director of NCI. We’re proud to have collaborated on hematology trials leading to approvals in Non-Hodgkin’s Lymphoma and wish him continued success at NCI.
Read More: https://t.co/VygiXmNbY5

[Imaging Endpoints @ImagingEndpoint]

We’re excited to connect at ESMO 2025 in Berlin, Oct 17–20!

Imaging Endpoints is the world’s largest oncology-focused imaging CRO, with an industry-leading >95% approval success rate.

Meet Dr. Ron Korn, CMO, to discuss your trial needs. https://t.co/x4NsHXZS7d

[Imaging Endpoints @ImagingEndpoint]

Evolving Pediatric Glioma Trial Assessments
RAPNO criteria address unique challenges in pediatric gliomas, guiding cystic tumor measurement and response tracking. With radiomics, Imaging Endpoints pioneered RAPNO use, supporting the first FDA approval.
https://t.co/fw7nVj2A7l

[Imaging Endpoints @ImagingEndpoint]

Splenomegaly is often overlooked in lymphoma trials.

At ECR2025, Dr. M. Sharma & Imaging Endpoints shared insights on integrating expert judgment with objective criteria to improve response assessments.

Read more: https://t.co/bDz41CM8BJ

ECR25 Poster: https://t.co/VWaFRP1pQL